Benson Investment Management Company Inc. held its stake in shares of Sanofi (NYSE:SNY) during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 2,340 shares of the company’s stock at the end of the second quarter. Benson Investment Management Company Inc.’s holdings in Sanofi were worth $112,000 at the end of the most recent quarter.
Other large investors have also made changes to their positions in the company. Fisher Asset Management LLC increased its stake in shares of Sanofi by 8.1% in the second quarter. Fisher Asset Management LLC now owns 13,638,458 shares of the company’s stock valued at $653,419,000 after buying an additional 1,022,953 shares during the period. Wells Fargo & Company MN boosted its position in Sanofi by 22.2% in the first quarter. Wells Fargo & Company MN now owns 4,492,719 shares of the company’s stock valued at $203,296,000 after buying an additional 815,820 shares in the last quarter. Global Financial Private Capital LLC purchased a new position in Sanofi during the first quarter valued at about $35,034,000. Karp Capital Management Corp bought a new position in shares of Sanofi during the first quarter worth about $26,174,000. Finally, Bank of America Corp DE boosted its position in shares of Sanofi by 8.2% in the first quarter. Bank of America Corp DE now owns 7,531,334 shares of the company’s stock worth $340,792,000 after buying an additional 572,652 shares during the period. Institutional investors and hedge funds own 9.96% of the company’s stock.
Sanofi (NYSE:SNY) traded up 0.30% during midday trading on Friday, hitting $47.55. 717,957 shares of the stock traded hands. The stock has a market cap of $119.42 billion, a PE ratio of 11.23 and a beta of 0.88. The company has a 50-day moving average of $47.99 and a 200-day moving average of $46.11. Sanofi has a 1-year low of $36.81 and a 1-year high of $50.24.
Sanofi (NYSE:SNY) last released its quarterly earnings data on Monday, July 31st. The company reported $0.74 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.74. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The company had revenue of $8.66 billion during the quarter, compared to the consensus estimate of $8.71 billion. The company’s quarterly revenue was down 2.3% compared to the same quarter last year. On average, equities analysts expect that Sanofi will post $3.26 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This article was first published by Stock Observer and is owned by of Stock Observer. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://www.thestockobserver.com/2017/08/12/sanofi-nysesny-stake-maintained-by-benson-investment-management-company-inc-updated-updated.html.
A number of brokerages have issued reports on SNY. Argus increased their target price on shares of Sanofi from $50.00 to $55.00 and gave the company a “buy” rating in a report on Friday, June 9th. Cowen and Company reissued a “market perform” rating and set a $52.00 price objective (up from $46.00) on shares of Sanofi in a research note on Tuesday, August 1st. TheStreet raised shares of Sanofi from a “c+” rating to a “b-” rating in a research note on Monday, April 24th. BidaskClub upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Saturday, August 5th. Finally, Zacks Investment Research lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Tuesday, April 25th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and five have assigned a buy rating to the company’s stock. Sanofi has a consensus rating of “Hold” and an average price target of $63.75.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.